Fate Therapeutics announces receipt of CIRM grant for clinical translation of FT516
Fate Therapeutics announced that the California Institute for Regenerative Medicine awarded the Company a $4.0 million grant to advance FT516 into a first-in-human clinical trial. FT516 is being developed as an off-the-shelf engineered NK cell cancer immunotherapy. February 23, 2018